Physician profile
Anna M Ketcham
NPI 1669859229
$12,907.27
in general payments reported to CMS, 2019-2025
28 companies · $2,996 in 2025
The $2,996 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,683 · 2022: $2,408 · 2023: $2,946 · 2024: $2,874 · 2025: $2,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,489 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,488.77 |
| Education | $327.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,533.94 | 2021-2025 | |
| Janssen Biotech, INC. | $1,312.87 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,280.55 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $929.48 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $802.41 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $726.02 | 2021-2025 | |
| Ucb, INC. | $724.13 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $717.44 | 2021-2025 | |
| Incyte Corporation | $594.69 | 2022-2025 | Opzelura |
| Amgen INC. | $587.42 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $394.44 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $390.11 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $354.50 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $331.09 | 2023-2025 | Sotyktu |
| Almirall LLC | $231.47 | 2021-2025 | Seysara, Klisyri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $150.00 | 2024 | Impella |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.62 | 2021-2023 | Arazlo |
| Mayne Pharma Commercial LLC | $141.94 | 2023-2025 | |
| Epi Health, LLC | $115.77 | 2021-2022 | |
| Galderma Laboratories, L.P. | $83.37 | 2021-2025 | Nemluvio |
| Medimetriks Pharmaceuticals, INC. | $82.24 | 2023 | Neo-Synalar |
| Genentech USA, INC. | $75.87 | 2023-2025 | Xolair |
| Organon LLC | $72.26 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $56.58 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2023-2024 | Cyltezo |
| Journey Medical Corporation | $16.94 | 2023 | |
| Dermira, INC. | $14.64 | 2021 | |
| Biofrontera INC. | $4.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ketcham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.